HT-29人结肠癌细胞

价 格:¥***

期 货:1周左右

保藏中心:BTCC

资源编号:BTCC-1075

产地:中国

套 餐:

细胞会员价 细胞非会员价 完全培养基500ml(仅供会员) 南美特级胎牛血清500ml(仅供会员)

详细资料说明书下载质检报告(COA)

Cell line nameHT-29
SynonymsHT 29; HT29
AccessionBTCC-1075
Resource Identification InitiativeTo cite this cell line use: HT-29 (BTCC-1075)
CommentsPart of: AstraZeneca Colorectal cell line (AZCL) panel.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR39 cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
From: Memorial Sloan Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 809.
Population: Caucasian.
Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257).
Doubling time: 36.93 hours (PubMed=25944804); 24 hours (PubMed=25984343); 24 hours (PubMed=23546019); 21.87 +- 0.12 hours (PubMed=32927768); ~24 hours (CLS=300215); ~40-60 hours (DSMZ=ACC-299); 19.5 hours (NCI-DTP=HT-29); ~23 hours (PBCF).
Karyotypic information: Hypertriploid karyotype.
Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=24755471; PubMed=25926053; PubMed=28683746; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Extracellular vesicles proteome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Caution: Indicated in PubMed=11921276 as originating from an adenocarcinoma of the rectosigmoid part of the intestine, but is only indicated in the oldest publication (DOI=10.1007/978-1-4757-1647-4_5) as a colon adenocarcinoma.
Misspelling: HCT29; GEO=GSM206503.
Derived from site: In situ; Colon; UBERON=UBERON_0001155.
Sequence variations
HLA typingSource: PubMed=77569
Class I
HLA-AA*01/11,03
HLA-BB*12,17

Source: PubMed=15748285
Class I
HLA-AA*01,24
HLA-BB*35,44:03:01
HLA-CC*04
Class II
HLA-DPDPB1*04:01
HLA-DQDQB1*02,03:02
HLA-DRDRB1*04:02,07:01

Source: PubMed=26589293
Class I
HLA-AA*01:01,24:03
HLA-BB*35:01,44:03
HLA-CC*04:01,04:01

Source: CLS=300215
Class I
HLA-AA*01:01:01,24:03:01
HLA-BB*35:01:01,44:03:01
HLA-CC*04:01:01
Class II
HLA-DPDPB1*04:01
HLA-DQDQA1*02:01:01,03:01:01

DQB1*02:02:01,03:02:01
HLA-DRDRB1*04:02:01,07:01:01
Genome ancestrySource: PubMed=30894373

Origin% genome


African1.57
Native American1.05
East Asian, North3.24
East Asian, South0
South Asian4.8
European, North26.11
European, South63.24
DiseaseColon adenocarcinoma (NCIt: C4349)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:



CVCL_9556 (2474/90)CVCL_9557 (2957/90)CVCL_9558 (3051/80)
CVCL_0144 (ARO)CVCL_2011 (CX-1)CVCL_DH88 (HT-29 BR100)
CVCL_DH89 (HT-29 BR200)CVCL_DH90 (HT-29 BR300)CVCL_H252 (HT-29 HD3)
CVCL_H253 (HT-29 HD4)CVCL_H254 (HT-29 HD6)CVCL_H255 (HT-29 HD8)
CVCL_C1KN (HT-29 Y1-16)CVCL_C1KP (HT-29 Y1-4)CVCL_C1KQ (HT-29 Y1-7)
CVCL_8118 (HT-29-D4)CVCL_4Z22 (HT-29-D9)CVCL_6833 (HT-29-G)
CVCL_J256 (HT-29-Luc)CVCL_5J34 (HT-29-luc-D6)CVCL_G077 (HT-29-M6)
CVCL_6834 (HT-29-MTX)CVCL_5J00 (HT-29-Red-FLuc)CVCL_0I27 (HT-29/5-FU)
CVCL_0T66 (HT-29/5-FU/S)CVCL_Y178 (HT-29/ADM)CVCL_LJ30 (HT-29/B6)
CVCL_Y177 (HT-29/cDDP)CVCL_DE12 (HT-29/cl.f8)CVCL_H269 (HT-29/CPT)
CVCL_Y179 (HT-29/ETP)CVCL_WV61 (HT-29/SN-38)CVCL_C3GK (HT-29_6244R)
CVCL_WN77 (HT-29KM)CVCL_EQ49 (HT-29R)CVCL_4V27 (HT-29R13)
CVCL_5U94 (HT29 LM1)CVCL_C764 (HT29-12B)CVCL_C765 (HT29-13G)
CVCL_C763 (HT29-16E)CVCL_5940 (HT29-18)CVCL_0323 (HT29-19A)
CVCL_A3CP (HT29-5FU resistant (1 microMolar))CVCL_A8P6 (HT29-5FU resistant (10 microMolar))CVCL_A8P9 (HT29-5M12)
CVCL_A8Q0 (HT29-5M21)CVCL_5J20 (HT29-luc2)CVCL_A8BX (HT29-Lucia AhR)
CVCL_5949 (HT29-OxR)CVCL_EQ23 (HT29-R)CVCL_2521 (HT29/219)
CVCL_4V74 (HT29/L-OHP)CVCL_8476 (HTOXAR3)CVCL_6301 (KAK-1)
CVCL_6302 (KAT-10)CVCL_6304 (KAT-4)CVCL_0370 (KAT-5)
CVCL_6305 (KAT-50)CVCL_6306 (KAT-7)CVCL_L095 (KM20)
CVCL_D889 (KM20L2)CVCL_YJ83 (LINTERNA HT-29)CVCL_6310 (MRO)
CVCL_7204 (MV-522)CVCL_M779 (RO-D81-1)CVCL_2760 (WiDr)
Sex of cellFemale
Age at sampling44Y
CategoryCancer cell line
STR profileSource(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=11416159; PubMed=19372543; PubMed=25877200; PubMed=25926053

Markers:
AmelogeninX
CSF1PO11,12
D1S165615,16
D2S44111
D2S133819,23
D3S135815,17
D5S81811,12
D7S82010
D8S117910 (AddexBio; CLS; DSMZ; PubMed=19372543; PubMed=25877200)
10,16 (CCRID; Genomics_Center_BCF_Technion; PubMed=11416159)
D10S124814,16
D12S39118.3,21
D13S31711 (AddexBio; CLS)
11,12 (ATCC; CCRID; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=19372543; PubMed=25877200; PubMed=25926053)
D16S53911,12
D18S5113
D19S43314
D21S1129,30
D22S104516
FGA20,22
Penta D11,13
Penta E14,16
TH016,9
TPOX8,9
vWA17,19

Run an STR similarity search on this cell line
Web pageshttps://en.wikipedia.org/wiki/HT-29
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://www.atcc.org/en/support/technical-support/faqs/htb-38-morphology-and-media
https://www.synapse.org/#!Synapse:syn31544471
https://strap.nci.nih.gov/celline_detail.php?sample_id=15
https://www.cellosaurus.org/pawefish/ColonCellLineDescriptions/HT29.html
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-32.html
https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-colorectal-adenocarcinoma-cell-line-ht-29
https://tcpaportal.org/mclp/
Publications

DOI=10.1007/978-1-4757-1647-4_5
Fogh J., Trempe G.L.
New human tumor cell lines.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)

PubMed=1159834; DOI=10.1093/jnci/55.3.555
von Kleist S., Chany E., Burtin P., King M., Fogh J.
Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor.
J. Natl. Cancer Inst. 55:555-560(1975)

PubMed=72600
Sharma B.
In vitro immunization against human tumor cells with tumor cell fractions.
Cancer Res. 37:4660-4668(1977)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=864752; DOI=10.1093/jnci/58.6.1743
Marshall C.J., Franks L.M., Carbonell A.W.
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.
J. Natl. Cancer Inst. 58:1743-1751(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=626984
Erickson L.C., Osieka R., Kohn K.W.
Differential repair of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1- nitrosourea-induced DNA damage in two human colon tumor cell lines.
Cancer Res. 38:802-808(1978)

PubMed=468301
Trejdosiewicz L.K., Trejdosiewicz A.J., Ling N.R., Dykes P.W.
Growth enhancing property of human monocytes from normal donors and cancer patients.
Immunology 37:247-252(1979)

PubMed=6256643; DOI=10.1038/288724a0
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.
Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.
Nature 288:724-727(1980)

PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6825208; DOI=10.1093/carcin/4.2.199
Yarosh D.B., Foote R.S., Mitra S., Day R.S. III
Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.
Carcinogenesis 4:199-205(1983)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3472642; DOI=10.1016/0165-4608(87)90267-6
Chen T.-R., Drabkowski D., Hay R.J., Macy M.L., Peterson W.D. Jr.
WiDr is a derivative of another colon adenocarcinoma cell line, HT-29.
Cancer Genet. Cytogenet. 27:125-134(1987)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=3349466
Chantret I., Barbat A., Dussaulx E., Brattain M.G., Zweibaum A.
Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines.
Cancer Res. 48:1936-1942(1988)

PubMed=2288877
Hafez M.M., Infante D., Winawer S., Friedman E.
Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation.
Cell Growth Differ. 1:617-626(1990)

PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x
Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M., Ohnishi Y., Xiao H.Y., Nagai Y., Takagi H.
Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells.
Jpn. J. Cancer Res. 82:1428-1435(1991)

PubMed=1937958; DOI=10.1002/ijc.2910490516
Lesuffleur T., Kornowski A., Luccioni C., Muleris M., Barbat A., Beaumatin J., Dussaulx E., Dutrillaux B., Zweibaum A.
Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation.
Int. J. Cancer 49:721-730(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=1389533; DOI=10.1016/0959-8049(92)90031-V
Lahm H., Petral-Malec D., Yilmaz-Ceyhan A., Fischer J.R., Lorenzoni M., Givel J.-C., Odartchenko N.
Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1.
Eur. J. Cancer 28:1894-1899(1992)

PubMed=1730571; DOI=10.1007/BF02631079
Goodwin T.J., Jessup J.M., Wolf D.A.
Morphologic differentiation of colon carcinoma cell lines HT-29 and HT-29KM in rotating-wall vessels.
In Vitro Cell. Dev. Biol. Anim. 28:47-60(1992)

PubMed=8464898; DOI=10.1073/pnas.90.7.2842
Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G., Bodmer W.F.
Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.
Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=7651727
Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.
Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.
Oncogene 11:647-652(1995)

PubMed=8895552; DOI=10.1002/(SICI)1097-0215(19960927)68:1<126::aid-ijc22>3.0.CO;2-8
Suardet L., Li C., Little J.B.
Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line.
Int. J. Cancer 68:126-131(1996)

PubMed=9000147
Cottu P.H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D., Thomas G., Hamelin R.
Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.
Oncogene 13:2727-2730(1996)

PubMed=9000572
Hoang J.-M., Cottu P.H., Thuille B., Salmon R.J., Thomas G., Hamelin R.
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.
Cancer Res. 57:300-303(1997)

PubMed=9294210; DOI=10.1073/pnas.94.19.10330
Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.
Beta-catenin mutations in cell lines established from human colorectal cancers.
Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

PubMed=10612807; DOI=10.1002/(SICI)1098-2264(200002)27:2<183::aid-gcc10>3.0.CO;2-P
Ghadimi B.M., Sackett D.L., Difilippantonio M.J., Schrock E., Neumann T., Jauho A., Auer G., Ried T.
Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations.
Genes Chromosomes Cancer 27:183-190(2000)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352
Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.
APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.
Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11226274; DOI=10.1073/pnas.041603298
Abdel-Rahman W.M., Katsura K., Rens W., Gorman P.A., Sheer D., Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.
Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11526487; DOI=10.1038/sj.onc.1204611
Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.H., Hamelin R.
Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.
Oncogene 20:5025-5032(2001)

PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)

PubMed=11921276; DOI=10.1002/gcc.10003
Kawai K., Viars C., Arden K., Tarin D., Urquidi V., Goodison S.
Comprehensive karyotyping of the HT-29 colon adenocarcinoma cell line.
Genes Chromosomes Cancer 34:1-8(2002)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16083285; DOI=10.1021/pr050048h
Kim J.-E., Tannenbaum S.R., White F.M.
Global phosphoproteome of HT-29 human colon adenocarcinoma cells.
J. Proteome Res. 4:1339-1346(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=18258742; DOI=10.1073/pnas.0712176105
Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19927377; DOI=10.1002/gcc.20730
Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.
Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.
Genes Chromosomes Cancer 49:204-223(2010)

PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022
Karger A., Bettin B., Lenk M., Mettenleiter T.C.
Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.
J. Virol. Methods 164:116-121(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192
Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Cancer Res. 70:5901-5911(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Br. J. Cancer 103:340-346(2010)

PubMed=20831567; DOI=10.1111/j.1582-4934.2010.01170.x
Ma Y.-L., Zhang P., Wang F., Moyer M.P., Yang J.-J., Liu Z.-H., Peng J.-Y., Chen H.-Q., Zhou Y.-K., Liu W.-J., Qin H.-L.
Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b.
J. Cell. Mol. Med. 15:1941-1954(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z
Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Invest. New Drugs 30:2035-2045(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23272949; DOI=10.1186/1755-8794-5-66
Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
BMC Med. Genomics 5:66.1-66.15(2012)

PubMed=22940288; DOI=10.1016/j.jsbmb.2012.08.003
Hobaus J., Fetahu I.S., Khorchide M., Manhardt T., Kallay E.
Epigenetic regulation of the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in colon cancer cells.
J. Steroid Biochem. Mol. Biol. 136:296-299(2013)

PubMed=23546019; DOI=10.3892/ijo.2013.1868
Petitprez A., Poindessous V., Ouaret D., Regairaz M., Bastian G., Guerin E., Escargueil A.E., Larsen A.K.
Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Int. J. Oncol. 42:1644-1653(2013)

PubMed=23631600; DOI=10.1021/pr400260h
Loftus N.J., Lai L., Wilkinson R.W., Odedra R., Wilson I.D., Barnes A.J.
Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS.
J. Proteome Res. 12:2980-2986(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23932154; DOI=10.1016/j.radonc.2013.06.032
Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A., Kitz J., Kaulfuss S., Beissbarth T., Dobbelstein M., Ghadimi M., Grade M., Gaedcke J.
Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
Radiother. Oncol. 108:451-457(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24042735; DOI=10.1038/oncsis.2013.35
Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.
Epigenetic and genetic features of 24 colon cancer cell lines.
Oncogenesis 2:e71.1-e71.8(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Cancer Res. 74:3238-3247(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25841592; DOI=10.1016/j.jprot.2015.03.019
Piersma S.R., Knol J.C., de Reus I., Labots M., Sampadi B.K., Pham T.V., Ishihama Y., Verheul H.M.W., Jimenez C.R.
Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines.
J. Proteomics 127:247-258(2015)

PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457
Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.
Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
Clin. Cancer Res. 21:3695-3704(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=29787047; DOI=10.1007/978-3-319-16104-4_11
Martinez-Maqueda D., Miralles B., Recio I.
HT29 cell line.
(In) The impact of food bioactives on health. In vitro and ex vivo models; Verhoeckx K., Cotter P., Lopez-Exposito I., Kleiveland C., Lea T., Mackie A., Requena T., Swiatecka D., Wichers H. (eds.); pp.113-124; Springer; Cham (2015)

PubMed=26537799; DOI=10.1074/mcp.M115.051235
Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A., Rombouts Y., Wuhrer M.
N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.
Mol. Cell. Proteomics 15:124-140(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578
Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B., Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R., Nagayama S., Fujita N., Sugimoto Y., Seimiya H.
APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.
Mol. Cancer Ther. 16:752-762(2017)

PubMed=28192450; DOI=10.1371/journal.pone.0171435
Fasterius E., Raso C., Kennedy S., Rauch N., Lundin P., Kolch W., Uhlen M., Al-Khalili Szigyarto C.
A novel RNA sequencing data analysis method for cell line authentication.
PLoS ONE 12:E0171435-E0171435(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28683746; DOI=10.1186/s12943-017-0691-y
Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.
Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.
Mol. Cancer 16:116.1-116.16(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010
Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Genomic determinants of protein abundance variation in colorectal cancer cells.
Cell Rep. 20:2201-2214(2017)

PubMed=29101300; DOI=10.15252/msb.20177701
Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.
Pharmacoproteomic characterisation of human colon and rectal cancer.
Mol. Syst. Biol. 13:951-951(2017)

PubMed=29207035; DOI=10.3892/ijo.2017.4206
Olejniczak A., Szarynska M., Kmiec Z.
In vitro characterization of spheres derived from colorectal cancer cell lines.
Int. J. Oncol. 52:599-612(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32172478; DOI=10.1007/s12253-020-00805-3
Xu Y.-T., Zhang L., Wang Q.-L., Zheng M.-J.
Comparison of different colorectal cancer with liver metastases models using six colorectal cancer cell lines.
Pathol. Oncol. Res. 26:2177-2183(2020)

PubMed=32927768; DOI=10.3390/cancers12092582
Schulte am Esch J., Windmoller B.A., Hanewinkel J., Storm J., Forster C., Wilkens L., Kruger M., Kaltschmidt B., Kaltschmidt C.
Isolation and characterization of two novel colorectal cancer cell lines, containing a subpopulation with potential stem-like properties: treatment options by MYC/NMYC inhibition.
Cancers (Basel) 12:2582.1-2582.34(2020)

PubMed=33389257; DOI=10.1007/s10096-020-04106-0
Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.
Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

PubMed=36648961; DOI=10.3390/proteomes11010003
Heck K.A., Lindholm H.T., Niederdorfer B., Tsirvouli E., Kuiper M., Flobak A., Laegreid A., Thommesen L.
Characterisation of colorectal cancer cell lines through proteomic profiling of their extracellular vesicles.
Proteomes 11:3.1-3.20(2023)

Cross-references
Cell line databases/resourcesCLO; CLO_0004283
MCCL; MCC:0000213
CLDB; cl1747
CLDB; cl1748
CLDB; cl1749
CLDB; cl1751
CLDB; cl1752
CLDB; cl1753
CLDB; cl1754
CLDB; cl4978
CLDB; cl5205
CCRID; 1101HUM-PUMC000109
CCRID; 3101HUMSCSP5032
CCRID; 3101HUMTCHu103
CCRID; 4201HUM-CCTCC00149
CCRID; 5301HUM-KCB05008YJ
Cell_Model_Passport; SIDM00136
ColonAtlas; HT29
Cosmic-CLP; 905939
DepMap; ACH-000552
DSMZCellDive; ACC-299
LINCS_LDP; LCL-1180
Lonza; 430
SKY/M-FISH/CGH; 1435
SKY/M-FISH/CGH; 2124
SKY/M-FISH/CGH; 2836
TOKU-E; 1968
Anatomy/cell type resourcesBTO; BTO:0000182
Biological sample resourcesBioSample; SAMN01821565
BioSample; SAMN03470953
BioSample; SAMN05292462
BioSample; SAMN10988348
ENCODE; ENCBS604AAA
ENCODE; ENCBS605AAA
ENCODE; ENCBS668UDT
ENCODE; ENCBS814TLB
ENCODE; ENCBS836FPI
ENCODE; ENCBS914HXH
Cell line collections (Providers)AddexBio; C0009004/48
ATCC; HTB-38
BCRJ; 0111
CCLV; CCLV-RIE 0960
CCTCC; GDC0149
CLS; 300215
DSMZ; ACC-299
ECACC; 91072201
IBRC; C10097
ICLC; HTL99026
IZSLER; BS TCL 132
KCB; KCB 200508YJ
KCLB; 30038
NCBI_Iran; C466
NCI-DTP; HT-29
Chemistry resourcesChEMBL-Cells; CHEMBL3307768
ChEMBL-Targets; CHEMBL384
GDSC; 905939
PharmacoDB; HT29_630_2019
PubChem_Cell_line; CVCL_0320
Encyclopedic resourcesWikidata; Q28334700
Experimental variables resourcesEFO; EFO_0001193

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部